Synthesis Peptides, a U.S. veteran-owned supplier of research peptides, has completed a full-catalog expansion of independent verification, bringing third-party laboratory testing to all 40-plus compounds in its lineup. Each batch now ships with a Certificate of Analysis documenting analytical peptide purity through both high-performance liquid chromatography (HPLC) and mass spectrometry protocols.
The rollout formalizes independent testing coverage across every compound currently listed in the research catalog. Each Certificate of Analysis is generated from data produced by external laboratories rather than internal assessments, establishing an objective documentation standard for scientific buyers sourcing compounds for in vitro laboratory work.
The dual-method testing approach applies two complementary analytical techniques to each peptide batch. HPLC separates compound components to identify and quantify impurities, while mass spectrometry confirms molecular identity by measuring the mass-to-charge ratio of ionized particles. Together, the two methods address both purity percentage and structural confirmation - two distinct dimensions of compound quality that bear directly on the reliability of downstream research outcomes.
All compounds supplied by Synthesis Peptides are intended strictly for in vitro research and laboratory use and are not approved for human or animal consumption, clinical application, or any use outside of controlled laboratory settings. The Certificates of Analysis accompany each order to allow researchers to assess compound specifications prior to experimental use.
Routing verification through independent third-party laboratory testing rather than relying solely on in-house analysis reflects a structural decision about how purity documentation is produced and presented. External laboratory involvement removes internal bias from the analytical process and gives research institutions, universities, and private laboratories an independently sourced data point when evaluating compound specifications.
Synthesis Peptides supplies more than 40 distinct peptide compounds, covering a range of sequences relevant to ongoing scientific inquiry in fields where in vitro experimentation is the standard research methodology. The Certificate of Analysis issued for each batch documents the specific purity percentage obtained through HPLC analysis alongside mass spectrometry confirmation of molecular weight, giving end users a complete analytical record for laboratory documentation purposes.
The analytical peptide purity standards applied across the catalog are consistent regardless of compound type or order volume, meaning a single-unit purchase carries the same Certificate of Analysis documentation as a bulk order. This uniformity in testing protocol across all 40-plus compounds is intended to give researchers a predictable documentation baseline when incorporating externally sourced research peptides into laboratory workflows.
Researchers accessing the catalog can review available compound listings and corresponding analytical documentation through the company's platform, where Certificate of Analysis records are made accessible alongside product specifications. The testing and documentation process functions as the baseline standard applied to every compound in the catalog, not as a selective or premium-tier offering.
Synthesis Peptides operates as a U.S. veteran-owned business, a designation that reflects the organizational structure and ownership of the company. The operational focus remains directed at the scientific research community, with catalog development, testing protocols, and documentation practices oriented toward institutional and professional research buyers rather than consumer markets.
For more information, visit Synthesis Peptides.
